Notice of Proposed Sale · 144
Gilead Sciences, Inc.
GILDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- GILEAD SCIENCES, INC.
- Issuer CIK
- 0000882095
- SEC file number
- 000-19731
- Phone
- (650) 574-3000
- Person for whose account securities are to be sold
- JOHANNA MERCIER
- Relationships to issuer
- Officer
- Street
- 333 Lakeside Drive
- City
- Foster City
- State / country code
- CA
- Postal code
- 94404
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,000 | 389,757.60 | 1,241,569,874 | 07/15/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 02/04/2025 | Performance Shares | ISSUER | 3,000 | N | 02/04/2025 | Not Applicable |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| JOHANNA MERCIER | Common | 06/15/2026 | 3,000 | 371,762.10 |
| JOHANNA MERCIER | Common | 05/15/2026 | 28,000 | 3,676,197.75 |
Seller — prior-sale row 1, entry 1
- Name
- JOHANNA MERCIER
- Street
- 333 Lakeside Drive
- City
- Foster City
- State / country code
- CA
- Postal code
- 94404
Seller — prior-sale row 2, entry 1
- Name
- JOHANNA MERCIER
- Street
- 333 Lakeside Drive
- City
- Foster City
- State / country code
- CA
- Postal code
- 94404
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/15/2026
- Signed
- /s/ Johanna Mercier
- Plan adoption dates
- 02/20/2025
Company context
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.